Log in
NASDAQ:BIVV

Bioverativ Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$104.98
0.00 (0.00 %)
(As of 03/19/2018)
Add
Today's Range
$104.98
Now: $104.98
$104.98
50-Day Range
$104.98
MA: $104.98
$104.98
52-Week Range
$48.14
Now: $104.98
$105.01
VolumeN/A
Average Volume3.03 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Read More
Bioverativ logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:BIVV
CUSIPN/A
Phone+1-781-6634400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BIVV News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bioverativ (NASDAQ:BIVV) Frequently Asked Questions

How were Bioverativ's earnings last quarter?

Bioverativ Inc (NASDAQ:BIVV) announced its quarterly earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.25. The biotechnology company earned $291.60 million during the quarter, compared to analysts' expectations of $285.45 million. The firm's revenue was up 27.2% on a year-over-year basis.
View Bioverativ's earnings history
.

What other stocks do shareholders of Bioverativ own?

Who are Bioverativ's key executives?

Bioverativ's management team includes the following people:
  • Brian S. Posner, Independent Chairman of the Board (Age 55)
  • John G. Cox, Chief Executive Officer, Director (Age 54)
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
  • Richard Brudnick, Executive Vice President - Business Development (Age 60)
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Louis J. Paglia, Independent Director (Age 59)

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

What is Bioverativ's stock price today?

One share of BIVV stock can currently be purchased for approximately $104.98.

What is Bioverativ's official website?

The official website for Bioverativ is www.bioverativ.com.

How can I contact Bioverativ?

Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.